Deltagen Inc. (DGEN) Stock Competitors & Peer Comparison
See (DGEN) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DGEN | $0.00 | +0.00% | 3.9K | N/A | N/A | N/A |
| SRTOY | $20.56 | +2.06% | 200B | 64.25 | $0.32 | +0.40% |
| ESLOY | $101.65 | +0.11% | 93.7B | 35.29 | $2.89 | +2.30% |
| ESLOF | $202.00 | +0.40% | 93.6B | 34.77 | $5.81 | +2.33% |
| SOAGY | $56.99 | +2.62% | 83.9B | 104.44 | $0.55 | +0.29% |
| HOCPY | $170.09 | -0.97% | 57B | 36.46 | $4.67 | +1.01% |
| HOCPF | $166.17 | +1.98% | 55.6B | 34.84 | $4.77 | +1.15% |
| MECNY | $88.63 | +0.00% | 26.9B | N/A | N/A | N/A |
| TRUMY | $15.04 | -0.66% | 22.3B | 26.07 | $0.58 | +1.14% |
| TRUMF | $15.12 | +2.30% | 22.3B | 26.07 | $0.58 | +1.29% |
Stock Comparison
DGEN vs SRTOY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SRTOY has a market cap of 200B. Regarding current trading prices, DGEN is priced at $0.00, while SRTOY trades at $20.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SRTOY's P/E ratio is 64.25. In terms of profitability, DGEN's ROE is +0.05%, compared to SRTOY's ROE of +0.06%. Regarding short-term risk, DGEN is less volatile compared to SRTOY. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check SRTOY's competition here
DGEN vs ESLOY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, ESLOY has a market cap of 93.7B. Regarding current trading prices, DGEN is priced at $0.00, while ESLOY trades at $101.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas ESLOY's P/E ratio is 35.29. In terms of profitability, DGEN's ROE is +0.05%, compared to ESLOY's ROE of +0.06%. Regarding short-term risk, DGEN is less volatile compared to ESLOY. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check ESLOY's competition here
DGEN vs ESLOF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, ESLOF has a market cap of 93.6B. Regarding current trading prices, DGEN is priced at $0.00, while ESLOF trades at $202.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas ESLOF's P/E ratio is 34.77. In terms of profitability, DGEN's ROE is +0.05%, compared to ESLOF's ROE of +0.06%. Regarding short-term risk, DGEN is less volatile compared to ESLOF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check ESLOF's competition here
DGEN vs SOAGY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SOAGY has a market cap of 83.9B. Regarding current trading prices, DGEN is priced at $0.00, while SOAGY trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SOAGY's P/E ratio is 104.44. In terms of profitability, DGEN's ROE is +0.05%, compared to SOAGY's ROE of +0.06%. Regarding short-term risk, DGEN is less volatile compared to SOAGY. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check SOAGY's competition here
DGEN vs HOCPY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, HOCPY has a market cap of 57B. Regarding current trading prices, DGEN is priced at $0.00, while HOCPY trades at $170.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas HOCPY's P/E ratio is 36.46. In terms of profitability, DGEN's ROE is +0.05%, compared to HOCPY's ROE of +0.25%. Regarding short-term risk, DGEN is less volatile compared to HOCPY. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check HOCPY's competition here
DGEN vs HOCPF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, HOCPF has a market cap of 55.6B. Regarding current trading prices, DGEN is priced at $0.00, while HOCPF trades at $166.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas HOCPF's P/E ratio is 34.84. In terms of profitability, DGEN's ROE is +0.05%, compared to HOCPF's ROE of +0.25%. Regarding short-term risk, DGEN and HOCPF have similar daily volatility (0.00).Check HOCPF's competition here
DGEN vs MECNY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, MECNY has a market cap of 26.9B. Regarding current trading prices, DGEN is priced at $0.00, while MECNY trades at $88.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas MECNY's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to MECNY's ROE of +0.02%. Regarding short-term risk, DGEN and MECNY have similar daily volatility (0.00).Check MECNY's competition here
DGEN vs TRUMY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, TRUMY has a market cap of 22.3B. Regarding current trading prices, DGEN is priced at $0.00, while TRUMY trades at $15.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas TRUMY's P/E ratio is 26.07. In terms of profitability, DGEN's ROE is +0.05%, compared to TRUMY's ROE of +0.09%. Regarding short-term risk, DGEN is less volatile compared to TRUMY. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check TRUMY's competition here
DGEN vs TRUMF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, TRUMF has a market cap of 22.3B. Regarding current trading prices, DGEN is priced at $0.00, while TRUMF trades at $15.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas TRUMF's P/E ratio is 26.07. In terms of profitability, DGEN's ROE is +0.05%, compared to TRUMF's ROE of +0.09%. Regarding short-term risk, DGEN is less volatile compared to TRUMF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check TRUMF's competition here
DGEN vs SDMHF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SDMHF has a market cap of 20B. Regarding current trading prices, DGEN is priced at $0.00, while SDMHF trades at $205.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SDMHF's P/E ratio is 63.95. In terms of profitability, DGEN's ROE is +0.05%, compared to SDMHF's ROE of +0.07%. Regarding short-term risk, DGEN is less volatile compared to SDMHF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check SDMHF's competition here
DGEN vs SAUHY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SAUHY has a market cap of 19.3B. Regarding current trading prices, DGEN is priced at $0.00, while SAUHY trades at $12.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SAUHY's P/E ratio is 43.21. In terms of profitability, DGEN's ROE is +0.05%, compared to SAUHY's ROE of +0.17%. Regarding short-term risk, DGEN is less volatile compared to SAUHY. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check SAUHY's competition here
DGEN vs SAUHF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SAUHF has a market cap of 19.1B. Regarding current trading prices, DGEN is priced at $0.00, while SAUHF trades at $119.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SAUHF's P/E ratio is 40.88. In terms of profitability, DGEN's ROE is +0.05%, compared to SAUHF's ROE of +0.17%. Regarding short-term risk, DGEN is less volatile compared to SAUHF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check SAUHF's competition here
DGEN vs SUVPF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SUVPF has a market cap of 18.9B. Regarding current trading prices, DGEN is priced at $0.00, while SUVPF trades at $273.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SUVPF's P/E ratio is 100.24. In terms of profitability, DGEN's ROE is +0.05%, compared to SUVPF's ROE of +0.06%. Regarding short-term risk, DGEN is less volatile compared to SUVPF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check SUVPF's competition here
DGEN vs SARTF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SARTF has a market cap of 15.7B. Regarding current trading prices, DGEN is priced at $0.00, while SARTF trades at $227.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SARTF's P/E ratio is 83.15. In terms of profitability, DGEN's ROE is +0.05%, compared to SARTF's ROE of +0.06%. Regarding short-term risk, DGEN and SARTF have similar daily volatility (0.00).Check SARTF's competition here
DGEN vs SSSGY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SSSGY has a market cap of 15.4B. Regarding current trading prices, DGEN is priced at $0.00, while SSSGY trades at $44.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SSSGY's P/E ratio is 81.24. In terms of profitability, DGEN's ROE is +0.05%, compared to SSSGY's ROE of +0.06%. Regarding short-term risk, DGEN is less volatile compared to SSSGY. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check SSSGY's competition here
DGEN vs FSPKF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, FSPKF has a market cap of 12.1B. Regarding current trading prices, DGEN is priced at $0.00, while FSPKF trades at $20.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas FSPKF's P/E ratio is 46.70. In terms of profitability, DGEN's ROE is +0.05%, compared to FSPKF's ROE of +0.23%. Regarding short-term risk, DGEN and FSPKF have similar daily volatility (0.00).Check FSPKF's competition here
DGEN vs AHICF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, AHICF has a market cap of 5.7B. Regarding current trading prices, DGEN is priced at $0.00, while AHICF trades at $21.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas AHICF's P/E ratio is 50.96. In terms of profitability, DGEN's ROE is +0.05%, compared to AHICF's ROE of +0.20%. Regarding short-term risk, DGEN is less volatile compared to AHICF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check AHICF's competition here
DGEN vs SSMXF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SSMXF has a market cap of 5.5B. Regarding current trading prices, DGEN is priced at $0.00, while SSMXF trades at $8.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SSMXF's P/E ratio is 24.58. In terms of profitability, DGEN's ROE is +0.05%, compared to SSMXF's ROE of +0.07%. Regarding short-term risk, DGEN is less volatile compared to SSMXF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check SSMXF's competition here
DGEN vs SSMXY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SSMXY has a market cap of 5.4B. Regarding current trading prices, DGEN is priced at $0.00, while SSMXY trades at $8.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SSMXY's P/E ratio is 24.22. In terms of profitability, DGEN's ROE is +0.05%, compared to SSMXY's ROE of +0.07%. Regarding short-term risk, DGEN is less volatile compared to SSMXY. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check SSMXY's competition here
DGEN vs CNVVY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, CNVVY has a market cap of 5.4B. Regarding current trading prices, DGEN is priced at $0.00, while CNVVY trades at $10.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas CNVVY's P/E ratio is 32.37. In terms of profitability, DGEN's ROE is +0.05%, compared to CNVVY's ROE of +0.10%. Regarding short-term risk, DGEN is less volatile compared to CNVVY. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check CNVVY's competition here
DGEN vs CNVVF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, CNVVF has a market cap of 5.1B. Regarding current trading prices, DGEN is priced at $0.00, while CNVVF trades at $2.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas CNVVF's P/E ratio is 29.06. In terms of profitability, DGEN's ROE is +0.05%, compared to CNVVF's ROE of +0.11%. Regarding short-term risk, DGEN is less volatile compared to CNVVF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check CNVVF's competition here
DGEN vs FLMNF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, FLMNF has a market cap of 4.3B. Regarding current trading prices, DGEN is priced at $0.00, while FLMNF trades at $50.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas FLMNF's P/E ratio is 17.87. In terms of profitability, DGEN's ROE is +0.05%, compared to FLMNF's ROE of +0.22%. Regarding short-term risk, DGEN is less volatile compared to FLMNF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check FLMNF's competition here
DGEN vs FLMNY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, FLMNY has a market cap of 4.2B. Regarding current trading prices, DGEN is priced at $0.00, while FLMNY trades at $9.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas FLMNY's P/E ratio is 17.43. In terms of profitability, DGEN's ROE is +0.05%, compared to FLMNY's ROE of +0.21%. Regarding short-term risk, DGEN is less volatile compared to FLMNY. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check FLMNY's competition here
DGEN vs ANSLF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, ANSLF has a market cap of 3.2B. Regarding current trading prices, DGEN is priced at $0.00, while ANSLF trades at $22.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas ANSLF's P/E ratio is 32.49. In terms of profitability, DGEN's ROE is +0.05%, compared to ANSLF's ROE of +0.07%. Regarding short-term risk, DGEN and ANSLF have similar daily volatility (0.00).Check ANSLF's competition here
DGEN vs ANSLY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, ANSLY has a market cap of 2.7B. Regarding current trading prices, DGEN is priced at $0.00, while ANSLY trades at $74.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas ANSLY's P/E ratio is 19.99. In terms of profitability, DGEN's ROE is +0.05%, compared to ANSLY's ROE of +0.07%. Regarding short-term risk, DGEN is less volatile compared to ANSLY. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check ANSLY's competition here
DGEN vs CZMWY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, CZMWY has a market cap of 2.6B. Regarding current trading prices, DGEN is priced at $0.00, while CZMWY trades at $30.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas CZMWY's P/E ratio is 16.15. In terms of profitability, DGEN's ROE is +0.05%, compared to CZMWY's ROE of +0.06%. Regarding short-term risk, DGEN is less volatile compared to CZMWY. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check CZMWY's competition here
DGEN vs CZMWF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, CZMWF has a market cap of 2.6B. Regarding current trading prices, DGEN is priced at $0.00, while CZMWF trades at $29.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas CZMWF's P/E ratio is 15.86. In terms of profitability, DGEN's ROE is +0.05%, compared to CZMWF's ROE of +0.07%. Regarding short-term risk, DGEN is less volatile compared to CZMWF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check CZMWF's competition here
DGEN vs EKTAF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, EKTAF has a market cap of 2.4B. Regarding current trading prices, DGEN is priced at $0.00, while EKTAF trades at $6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas EKTAF's P/E ratio is -43.33. In terms of profitability, DGEN's ROE is +0.05%, compared to EKTAF's ROE of -0.06%. Regarding short-term risk, DGEN and EKTAF have similar daily volatility (0.00).Check EKTAF's competition here
DGEN vs EKTAY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, EKTAY has a market cap of 2.2B. Regarding current trading prices, DGEN is priced at $0.00, while EKTAY trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas EKTAY's P/E ratio is -38.35. In terms of profitability, DGEN's ROE is +0.05%, compared to EKTAY's ROE of -0.00%. Regarding short-term risk, DGEN and EKTAY have similar daily volatility (0.00).Check EKTAY's competition here
DGEN vs SHWGF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SHWGF has a market cap of 2B. Regarding current trading prices, DGEN is priced at $0.00, while SHWGF trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SHWGF's P/E ratio is 8.80. In terms of profitability, DGEN's ROE is +0.05%, compared to SHWGF's ROE of +0.07%. Regarding short-term risk, DGEN is less volatile compared to SHWGF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check SHWGF's competition here
DGEN vs ADDLF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, ADDLF has a market cap of 1.8B. Regarding current trading prices, DGEN is priced at $0.00, while ADDLF trades at $15.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas ADDLF's P/E ratio is 23.16. In terms of profitability, DGEN's ROE is +0.05%, compared to ADDLF's ROE of +0.11%. Regarding short-term risk, DGEN is less volatile compared to ADDLF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check ADDLF's competition here
DGEN vs SHWGY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SHWGY has a market cap of 1.8B. Regarding current trading prices, DGEN is priced at $0.00, while SHWGY trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SHWGY's P/E ratio is 7.67. In terms of profitability, DGEN's ROE is +0.05%, compared to SHWGY's ROE of +0.07%. Regarding short-term risk, DGEN is less volatile compared to SHWGY. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check SHWGY's competition here
DGEN vs NPRRF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, NPRRF has a market cap of 1.6B. Regarding current trading prices, DGEN is priced at $0.00, while NPRRF trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas NPRRF's P/E ratio is 21.65. In terms of profitability, DGEN's ROE is +0.05%, compared to NPRRF's ROE of N/A. Regarding short-term risk, DGEN is less volatile compared to NPRRF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check NPRRF's competition here
DGEN vs TGLVY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, TGLVY has a market cap of 1.6B. Regarding current trading prices, DGEN is priced at $0.00, while TGLVY trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas TGLVY's P/E ratio is 40.00. In terms of profitability, DGEN's ROE is +0.05%, compared to TGLVY's ROE of +0.03%. Regarding short-term risk, DGEN and TGLVY have similar daily volatility (0.00).Check TGLVY's competition here
DGEN vs BITGF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, BITGF has a market cap of 1.2B. Regarding current trading prices, DGEN is priced at $0.00, while BITGF trades at $15.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas BITGF's P/E ratio is 45.50. In terms of profitability, DGEN's ROE is +0.05%, compared to BITGF's ROE of +0.04%. Regarding short-term risk, DGEN is less volatile compared to BITGF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check BITGF's competition here
DGEN vs PBHDF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, PBHDF has a market cap of 1.2B. Regarding current trading prices, DGEN is priced at $0.00, while PBHDF trades at $19.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas PBHDF's P/E ratio is 12.74. In terms of profitability, DGEN's ROE is +0.05%, compared to PBHDF's ROE of +0.07%. Regarding short-term risk, DGEN and PBHDF have similar daily volatility (0.00).Check PBHDF's competition here
DGEN vs SAFLY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SAFLY has a market cap of 1.1B. Regarding current trading prices, DGEN is priced at $0.00, while SAFLY trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SAFLY's P/E ratio is 13.93. In terms of profitability, DGEN's ROE is +0.05%, compared to SAFLY's ROE of +0.12%. Regarding short-term risk, DGEN is less volatile compared to SAFLY. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check SAFLY's competition here
DGEN vs GRRMF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, GRRMF has a market cap of 1.1B. Regarding current trading prices, DGEN is priced at $0.00, while GRRMF trades at $32.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas GRRMF's P/E ratio is 40.76. In terms of profitability, DGEN's ROE is +0.05%, compared to GRRMF's ROE of +0.02%. Regarding short-term risk, DGEN and GRRMF have similar daily volatility (0.00).Check GRRMF's competition here
DGEN vs JNDOF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, JNDOF has a market cap of 1.1B. Regarding current trading prices, DGEN is priced at $0.00, while JNDOF trades at $47.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas JNDOF's P/E ratio is 98.38. In terms of profitability, DGEN's ROE is +0.05%, compared to JNDOF's ROE of +0.27%. Regarding short-term risk, DGEN and JNDOF have similar daily volatility (0.00).Check JNDOF's competition here
DGEN vs SAFLF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SAFLF has a market cap of 906.6M. Regarding current trading prices, DGEN is priced at $0.00, while SAFLF trades at $2.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SAFLF's P/E ratio is 16.50. In terms of profitability, DGEN's ROE is +0.05%, compared to SAFLF's ROE of +0.12%. Regarding short-term risk, DGEN and SAFLF have similar daily volatility (0.00).Check SAFLF's competition here
DGEN vs KSRBF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, KSRBF has a market cap of 839.6M. Regarding current trading prices, DGEN is priced at $0.00, while KSRBF trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas KSRBF's P/E ratio is 33.29. In terms of profitability, DGEN's ROE is +0.05%, compared to KSRBF's ROE of +0.04%. Regarding short-term risk, DGEN and KSRBF have similar daily volatility (0.00).Check KSRBF's competition here
DGEN vs TDVXF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, TDVXF has a market cap of 833.9M. Regarding current trading prices, DGEN is priced at $0.00, while TDVXF trades at $7.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas TDVXF's P/E ratio is 43.89. In terms of profitability, DGEN's ROE is +0.05%, compared to TDVXF's ROE of +0.32%. Regarding short-term risk, DGEN is less volatile compared to TDVXF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check TDVXF's competition here
DGEN vs HGYMF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, HGYMF has a market cap of 754.4M. Regarding current trading prices, DGEN is priced at $0.00, while HGYMF trades at $34.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas HGYMF's P/E ratio is 184.16. In terms of profitability, DGEN's ROE is +0.05%, compared to HGYMF's ROE of +0.00%. Regarding short-term risk, DGEN is less volatile compared to HGYMF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check HGYMF's competition here
DGEN vs NNCSF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, NNCSF has a market cap of 747M. Regarding current trading prices, DGEN is priced at $0.00, while NNCSF trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas NNCSF's P/E ratio is 50.00. In terms of profitability, DGEN's ROE is +0.05%, compared to NNCSF's ROE of +0.10%. Regarding short-term risk, DGEN and NNCSF have similar daily volatility (0.00).Check NNCSF's competition here
DGEN vs SPMXF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SPMXF has a market cap of 458.6M. Regarding current trading prices, DGEN is priced at $0.00, while SPMXF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SPMXF's P/E ratio is -15.00. In terms of profitability, DGEN's ROE is +0.05%, compared to SPMXF's ROE of -0.08%. Regarding short-term risk, DGEN is less volatile compared to SPMXF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check SPMXF's competition here
DGEN vs CLHLF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, CLHLF has a market cap of 365.5M. Regarding current trading prices, DGEN is priced at $0.00, while CLHLF trades at $61.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas CLHLF's P/E ratio is 27.93. In terms of profitability, DGEN's ROE is +0.05%, compared to CLHLF's ROE of +0.16%. Regarding short-term risk, DGEN and CLHLF have similar daily volatility (0.00).Check CLHLF's competition here
DGEN vs TSNLF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, TSNLF has a market cap of 265.4M. Regarding current trading prices, DGEN is priced at $0.00, while TSNLF trades at $5.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas TSNLF's P/E ratio is 25.14. In terms of profitability, DGEN's ROE is +0.05%, compared to TSNLF's ROE of +0.24%. Regarding short-term risk, DGEN is less volatile compared to TSNLF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check TSNLF's competition here
DGEN vs OPSSF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, OPSSF has a market cap of 247.4M. Regarding current trading prices, DGEN is priced at $0.00, while OPSSF trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas OPSSF's P/E ratio is -26.74. In terms of profitability, DGEN's ROE is +0.05%, compared to OPSSF's ROE of -0.36%. Regarding short-term risk, DGEN is less volatile compared to OPSSF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check OPSSF's competition here
DGEN vs EEOIF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, EEOIF has a market cap of 63.4M. Regarding current trading prices, DGEN is priced at $0.00, while EEOIF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas EEOIF's P/E ratio is -2.42. In terms of profitability, DGEN's ROE is +0.05%, compared to EEOIF's ROE of N/A. Regarding short-term risk, DGEN and EEOIF have similar daily volatility (0.00).Check EEOIF's competition here
DGEN vs OTCFF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, OTCFF has a market cap of 20.9M. Regarding current trading prices, DGEN is priced at $0.00, while OTCFF trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas OTCFF's P/E ratio is -13.07. In terms of profitability, DGEN's ROE is +0.05%, compared to OTCFF's ROE of +1.38%. Regarding short-term risk, DGEN is less volatile compared to OTCFF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check OTCFF's competition here
DGEN vs UEEC Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, UEEC has a market cap of 16.4M. Regarding current trading prices, DGEN is priced at $0.00, while UEEC trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas UEEC's P/E ratio is -6.28. In terms of profitability, DGEN's ROE is +0.05%, compared to UEEC's ROE of +0.40%. Regarding short-term risk, DGEN is less volatile compared to UEEC. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check UEEC's competition here
DGEN vs BLMHF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, BLMHF has a market cap of 5.2M. Regarding current trading prices, DGEN is priced at $0.00, while BLMHF trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas BLMHF's P/E ratio is 1.56. In terms of profitability, DGEN's ROE is +0.05%, compared to BLMHF's ROE of N/A. Regarding short-term risk, DGEN and BLMHF have similar daily volatility (0.00).Check BLMHF's competition here
DGEN vs PXMVF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, PXMVF has a market cap of 4.6M. Regarding current trading prices, DGEN is priced at $0.00, while PXMVF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas PXMVF's P/E ratio is -0.17. In terms of profitability, DGEN's ROE is +0.05%, compared to PXMVF's ROE of -6.46%. Regarding short-term risk, DGEN is less volatile compared to PXMVF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check PXMVF's competition here
DGEN vs MCDA Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, MCDA has a market cap of 4.2M. Regarding current trading prices, DGEN is priced at $0.00, while MCDA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas MCDA's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to MCDA's ROE of N/A. Regarding short-term risk, DGEN and MCDA have similar daily volatility (0.00).Check MCDA's competition here
DGEN vs TUTH Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, TUTH has a market cap of 4.2M. Regarding current trading prices, DGEN is priced at $0.00, while TUTH trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas TUTH's P/E ratio is -1.67. In terms of profitability, DGEN's ROE is +0.05%, compared to TUTH's ROE of +0.27%. Regarding short-term risk, DGEN and TUTH have similar daily volatility (0.00).Check TUTH's competition here
DGEN vs RSCF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, RSCF has a market cap of 4.1M. Regarding current trading prices, DGEN is priced at $0.00, while RSCF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas RSCF's P/E ratio is -4.75. In terms of profitability, DGEN's ROE is +0.05%, compared to RSCF's ROE of +0.10%. Regarding short-term risk, DGEN is less volatile compared to RSCF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check RSCF's competition here
DGEN vs CBSC Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, CBSC has a market cap of 3.6M. Regarding current trading prices, DGEN is priced at $0.00, while CBSC trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas CBSC's P/E ratio is -3.20. In terms of profitability, DGEN's ROE is +0.05%, compared to CBSC's ROE of +0.58%. Regarding short-term risk, DGEN is less volatile compared to CBSC. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check CBSC's competition here
DGEN vs NSTGQ Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, NSTGQ has a market cap of 3.3M. Regarding current trading prices, DGEN is priced at $0.00, while NSTGQ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas NSTGQ's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to NSTGQ's ROE of N/A. Regarding short-term risk, DGEN is less volatile compared to NSTGQ. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check NSTGQ's competition here
DGEN vs GVDI Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, GVDI has a market cap of 2.2M. Regarding current trading prices, DGEN is priced at $0.00, while GVDI trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas GVDI's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to GVDI's ROE of +0.00%. Regarding short-term risk, DGEN is less volatile compared to GVDI. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check GVDI's competition here
DGEN vs YBGJ Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, YBGJ has a market cap of 1M. Regarding current trading prices, DGEN is priced at $0.00, while YBGJ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas YBGJ's P/E ratio is -0.84. In terms of profitability, DGEN's ROE is +0.05%, compared to YBGJ's ROE of +0.37%. Regarding short-term risk, DGEN and YBGJ have similar daily volatility (0.00).Check YBGJ's competition here
DGEN vs OJSY Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, OJSY has a market cap of 454.3K. Regarding current trading prices, DGEN is priced at $0.00, while OJSY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas OJSY's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to OJSY's ROE of N/A. Regarding short-term risk, DGEN and OJSY have similar daily volatility (0.00).Check OJSY's competition here
DGEN vs PDMI Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, PDMI has a market cap of 324.9K. Regarding current trading prices, DGEN is priced at $0.00, while PDMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas PDMI's P/E ratio is -0.01. In terms of profitability, DGEN's ROE is +0.05%, compared to PDMI's ROE of +0.19%. Regarding short-term risk, DGEN and PDMI have similar daily volatility (0.00).Check PDMI's competition here
DGEN vs WHSI Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, WHSI has a market cap of 182.7K. Regarding current trading prices, DGEN is priced at $0.00, while WHSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas WHSI's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to WHSI's ROE of +0.84%. Regarding short-term risk, DGEN and WHSI have similar daily volatility (0.00).Check WHSI's competition here
DGEN vs BLFE Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, BLFE has a market cap of 156.7K. Regarding current trading prices, DGEN is priced at $0.00, while BLFE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas BLFE's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to BLFE's ROE of +3.67%. Regarding short-term risk, DGEN and BLFE have similar daily volatility (0.00).Check BLFE's competition here
DGEN vs ECIA Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, ECIA has a market cap of 124.5K. Regarding current trading prices, DGEN is priced at $0.00, while ECIA trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas ECIA's P/E ratio is -0.33. In terms of profitability, DGEN's ROE is +0.05%, compared to ECIA's ROE of -0.22%. Regarding short-term risk, DGEN is less volatile compared to ECIA. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check ECIA's competition here
DGEN vs QTXB Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, QTXB has a market cap of 118K. Regarding current trading prices, DGEN is priced at $0.00, while QTXB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas QTXB's P/E ratio is -0.05. In terms of profitability, DGEN's ROE is +0.05%, compared to QTXB's ROE of +0.19%. Regarding short-term risk, DGEN is less volatile compared to QTXB. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check QTXB's competition here
DGEN vs LANZ Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, LANZ has a market cap of 110.4K. Regarding current trading prices, DGEN is priced at $0.00, while LANZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas LANZ's P/E ratio is 4.00. In terms of profitability, DGEN's ROE is +0.05%, compared to LANZ's ROE of +0.01%. Regarding short-term risk, DGEN is less volatile compared to LANZ. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check LANZ's competition here
DGEN vs CEOS Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, CEOS has a market cap of 90.4K. Regarding current trading prices, DGEN is priced at $0.00, while CEOS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas CEOS's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to CEOS's ROE of +7.33%. Regarding short-term risk, DGEN and CEOS have similar daily volatility (0.00).Check CEOS's competition here
DGEN vs IMTH Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, IMTH has a market cap of 71.8K. Regarding current trading prices, DGEN is priced at $0.00, while IMTH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas IMTH's P/E ratio is -0.02. In terms of profitability, DGEN's ROE is +0.05%, compared to IMTH's ROE of -0.60%. Regarding short-term risk, DGEN and IMTH have similar daily volatility (0.00).Check IMTH's competition here
DGEN vs GMVDF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, GMVDF has a market cap of 26K. Regarding current trading prices, DGEN is priced at $0.00, while GMVDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas GMVDF's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to GMVDF's ROE of +3.68%. Regarding short-term risk, DGEN and GMVDF have similar daily volatility (0.00).Check GMVDF's competition here
DGEN vs REMI Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, REMI has a market cap of 14K. Regarding current trading prices, DGEN is priced at $0.00, while REMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas REMI's P/E ratio is -0.07. In terms of profitability, DGEN's ROE is +0.05%, compared to REMI's ROE of -0.11%. Regarding short-term risk, DGEN is less volatile compared to REMI. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check REMI's competition here
DGEN vs SDCCQ Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SDCCQ has a market cap of 13.4K. Regarding current trading prices, DGEN is priced at $0.00, while SDCCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SDCCQ's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to SDCCQ's ROE of -0.61%. Regarding short-term risk, DGEN and SDCCQ have similar daily volatility (0.00).Check SDCCQ's competition here
DGEN vs MDIT Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, MDIT has a market cap of 8.7K. Regarding current trading prices, DGEN is priced at $0.00, while MDIT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas MDIT's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to MDIT's ROE of -0.99%. Regarding short-term risk, DGEN and MDIT have similar daily volatility (0.00).Check MDIT's competition here
DGEN vs ASFX Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, ASFX has a market cap of 5.3K. Regarding current trading prices, DGEN is priced at $0.00, while ASFX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas ASFX's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to ASFX's ROE of +0.00%. Regarding short-term risk, DGEN is less volatile compared to ASFX. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check ASFX's competition here
DGEN vs SVSO Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SVSO has a market cap of 2.6K. Regarding current trading prices, DGEN is priced at $0.00, while SVSO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SVSO's P/E ratio is -0.01. In terms of profitability, DGEN's ROE is +0.05%, compared to SVSO's ROE of +0.17%. Regarding short-term risk, DGEN and SVSO have similar daily volatility (0.00).Check SVSO's competition here
DGEN vs LFPI Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, LFPI has a market cap of 2.1K. Regarding current trading prices, DGEN is priced at $0.00, while LFPI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas LFPI's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to LFPI's ROE of -4.85%. Regarding short-term risk, DGEN is less volatile compared to LFPI. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check LFPI's competition here
DGEN vs SEYE Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SEYE has a market cap of 1.2K. Regarding current trading prices, DGEN is priced at $0.00, while SEYE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SEYE's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to SEYE's ROE of N/A. Regarding short-term risk, DGEN and SEYE have similar daily volatility (0.00).Check SEYE's competition here
DGEN vs BGMD Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, BGMD has a market cap of 1.1K. Regarding current trading prices, DGEN is priced at $0.00, while BGMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas BGMD's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to BGMD's ROE of +7.47%. Regarding short-term risk, DGEN and BGMD have similar daily volatility (0.00).Check BGMD's competition here
DGEN vs ADLI Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, ADLI has a market cap of 1K. Regarding current trading prices, DGEN is priced at $0.00, while ADLI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas ADLI's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to ADLI's ROE of +1.36%. Regarding short-term risk, DGEN is less volatile compared to ADLI. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check ADLI's competition here
DGEN vs VSMD Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, VSMD has a market cap of 802. Regarding current trading prices, DGEN is priced at $0.00, while VSMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas VSMD's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to VSMD's ROE of +3.15%. Regarding short-term risk, DGEN is less volatile compared to VSMD. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check VSMD's competition here
DGEN vs TEVNF Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, TEVNF has a market cap of 744. Regarding current trading prices, DGEN is priced at $0.00, while TEVNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas TEVNF's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to TEVNF's ROE of +3.22%. Regarding short-term risk, DGEN is less volatile compared to TEVNF. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check TEVNF's competition here
DGEN vs MICRD Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, MICRD has a market cap of 317. Regarding current trading prices, DGEN is priced at $0.00, while MICRD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas MICRD's P/E ratio is -0.00. In terms of profitability, DGEN's ROE is +0.05%, compared to MICRD's ROE of -0.25%. Regarding short-term risk, DGEN and MICRD have similar daily volatility (0.00).Check MICRD's competition here
DGEN vs INND Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, INND has a market cap of 306. Regarding current trading prices, DGEN is priced at $0.00, while INND trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas INND's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to INND's ROE of -0.01%. Regarding short-term risk, DGEN is less volatile compared to INND. This indicates potentially lower risk in terms of short-term price fluctuations for DGEN.Check INND's competition here
DGEN vs HRAL Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, HRAL has a market cap of 297. Regarding current trading prices, DGEN is priced at $0.00, while HRAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas HRAL's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to HRAL's ROE of +0.21%. Regarding short-term risk, DGEN and HRAL have similar daily volatility (0.00).Check HRAL's competition here
DGEN vs RGBOQ Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, RGBOQ has a market cap of 97. Regarding current trading prices, DGEN is priced at $0.00, while RGBOQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas RGBOQ's P/E ratio is -0.00. In terms of profitability, DGEN's ROE is +0.05%, compared to RGBOQ's ROE of N/A. Regarding short-term risk, DGEN and RGBOQ have similar daily volatility (0.00).Check RGBOQ's competition here
DGEN vs SECI Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, SECI has a market cap of 31. Regarding current trading prices, DGEN is priced at $0.00, while SECI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas SECI's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to SECI's ROE of -0.00%. Regarding short-term risk, DGEN and SECI have similar daily volatility (0.00).Check SECI's competition here
DGEN vs VTEQ Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, VTEQ has a market cap of 1. Regarding current trading prices, DGEN is priced at $0.00, while VTEQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas VTEQ's P/E ratio is -0.00. In terms of profitability, DGEN's ROE is +0.05%, compared to VTEQ's ROE of N/A. Regarding short-term risk, DGEN and VTEQ have similar daily volatility (0.00).Check VTEQ's competition here
DGEN vs MEDVD Comparison June 2026
DGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGEN stands at 3.9K. In comparison, MEDVD has a market cap of 0. Regarding current trading prices, DGEN is priced at $0.00, while MEDVD trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGEN currently has a P/E ratio of N/A, whereas MEDVD's P/E ratio is N/A. In terms of profitability, DGEN's ROE is +0.05%, compared to MEDVD's ROE of N/A. Regarding short-term risk, DGEN and MEDVD have similar daily volatility (0.00).Check MEDVD's competition here